coteauBeta Get App
SUPN

SUPN

Supernus Pharmaceuticals, Inc.
$41.21
-0.05% Oct 21 close
Health CareS&P 600 Compare
1M3M6M1Y2Y
-27%-16%-5%+6%+17%Oct 2025Oct 2026Apr 2026
SUPNSPY
1W
+2.6%
1M
-3.7%
3M
-12.2%
6M
-18.1%
YTD
-17.1%
1Y
-18.7%

Live chart

Loading live chart…

What they do

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD).

Healthcare · Drug Manufacturers - Specialty & Generic

For information only · Important disclosures

Grades vs sector

Momentum
12th percentile in sector
D-
12-1 return: -21.9%
Percentile within its GICS sector across the S&P 1500.
Growth
90th percentile in sector
A
Revenue growth (YoY): +32.4%
Percentile within its GICS sector across the S&P 1500.
Value
67th percentile in sector
B
Forward E/P: 11.4% · EBITDA/EV: 5.9%
Percentile within its GICS sector across the S&P 1500.
Profitability
11th percentile in sector
D-
Profit margin: -13.2% · Return on equity: -10.5%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Our models

Held by 1 of 5 live models: New Highs Growth.

New Highs Growth
4.0% of the book
 HeldQuality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 Coteau Long Book
Not in the current book
Why it's in the New Highs Growth

Qualified on Pharma, -24% from 52-week high, held: still within 25% of its high, 12-1 momentum -7%.

What would knock it out: Drops out if it falls outside the top 25 at the next rebalance (Oct 30). In the latest preview (2026-10-20) it is outside the top 25.

News

More news
No recent headlines.

Key stats

52-week range$37.88 – $57.00
Valuation and fundamentals

Valuation & fundamentals

Bottom line
Leans expensive
Model read-out from the numbers below, not advice. Score -2 (DCF counts double).
▼DCF (base case)below the price by 82%
•Piotroski F-score4/9

Discounted cash flow

Bear
$6
-86%
growth -2% · disc. 10.2% · term. 2.0%
Base
$7
-82%
growth 3% · disc. 9.2% · term. 2.5%
Bull
$10
-76%
growth 6% · disc. 8.2% · term. 3.0%

A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.

Reverse DCFfor context, not a signal
Not enough data to run a reverse DCF.
Edit assumptions · recalculates instantly
Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.00 (n/a) × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs Health Care

P/E (trailing)
sector median 29.9×
 –
Forward P/E
sector median 17.6×
 –
EV / EBITDA
sector median 15.8×
 –
Price / sales
sector median 3.1×
 –
Price / book
sector median 3.5×
 –
FCF yield
sector median 4.1%
 –

Quality & financial health

Gross margin
88.1%
Operating margin
-15.7%
FCF margin
2.3%
Net margin
-13.2%
Return on equity
-10.7%
Return on invested capital
-11.7%
Net debt / EBITDA
–
Current ratio
2.1×
Interest cover
-56.4×
Cash conversion (OCF/NI)
–
Piotroski F-score 4/9 · last two fiscal years
✗ Positive net income✓ Positive operating cash flow✗ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✗ Current ratio improved✗ No share dilution✗ Gross margin improved✓ Asset turnover improved

Analysts

No analyst targets available.

Annual history

FYRevenueNet incomeFree cash flow
2025$719.0M$-38.5M$46.0M
2024$661.8M$73.9M$171.2M
2023$607.5M$1.3M$110.5M
2022$667.2M$60.7M$116.4M
2021$579.8M$53.4M$127.1M
2020$520.4M$127.0M$134.9M

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +2.5%.

Earnings

Next report: 2026-10-29 · after close · EPS est 0.49
24-1125-0225-0525-0825-1126-0226-0526-080.001.10
EstimateActual (beat)Actual (miss)
ReportEPS estActualSurprise
2026-08-030.510.53+4.1%
2026-05-050.280.21-24.5%
2026-02-240.280.88+215.0%
2025-11-040.820.61-25.9%
2025-08-050.470.91+94.8%
2025-05-060.370.44+16.9%
2025-02-250.520.55+5.4%
2024-11-040.441.10+147.5%
Insider trades
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–

Stats refreshed 2026-10-21 18:16:44 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Free. Not investment advice. Unsubscribe anytime.

coteau

Independent research · Not investment advice · Important disclosures · Contact desk@coteau.app

Coteau Systematic Strategies publishes stock research and model portfolios. Results are hypothetical unless marked Live. Data: Yahoo Finance (15-min delayed), SEC EDGAR and the House Clerk.

How it worksDisclaimerTermsPrivacyData statusSend feedback
Beta 0.9 · Oct 21, 2026